Obesity and Adipose Tissue-Derived Cytokines in the Pathogenesis of Multiple Sclerosis Publisher Pubmed



Daryabor G¹ ; Amirghofran Z^{1, 2} ; Gholijani N¹ ; Bemani P³ Show Affiliations
Source: Endocrine, Metabolic and Immune Disorders - Drug Targets Published:2022

Abstract

Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative disease of the central nervous system (CNS) characterized by demyelination, neuronal loss, and permanent neu-rological impairments. The etiology of MS is not clearly understood, but genetics and environmental factors can affect the susceptibility of individuals. Obesity or a body mass index of (BMI) > 30 kg/m2 is associated with serious health consequences such as lipid profile abnormal-ities, hypertension, type 2 diabetes mellitus, reduced levels of vitamin D, and a systemic low-grade inflammatory state. The inflammatory milieu can negatively affect the CNS and promote MS pathogenesis due in part to the increased blood-brain barrier permeability by the actions of adipose tissue-derived cytokines or adipokines. By crossing the blood-brain barrier, the pro-in-flammatory adipokines such as leptin, resistin, and visfatin activate the CNS-resident immune cells, and promote the inflammatory responses; subsequently, demyelinating lesions occur in the white matter of the brain and spinal cord. Therefore, better knowledge of the adipokines’ role in the induction of obesity‐related chronic inflammation and subsequent events leading to the dys-functional blood-brain barrier is essential. In this review, recent evidence regarding the possible roles of obesity and its related systemic low-grade inflammation, and the roles of adipokines and their genetic variants in the modulation of immune responses and altered blood-brain barrier permeability in MS patients, has been elucidated. Besides, the results of the current studies regarding the potential use of adipokines in predicting MS disease severity and response to treatment have been explored. © 2022 Bentham Science Publishers.